Twist, Serimmune identify SARS-CoV-2 antibody therapies

By The Science Advisory Board staff writers

June 9, 2020 -- Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.

Existing Twist antibody candidates that bind with high affinity to either the SARS-CoV-2 S1 spike protein or the human angiotensin-converting enzyme 2 (ACE2) cellular receptor will be evaluated using Serimmune's Serum Epitope Repertoire Analysis (SERA) platforms. Those epitopes that are identified in the first phase of the collaboration will then be used to rescreen Twist's proprietary synthetic antibody discovery libraries to identify and evaluate new candidates, while also further increasing the specificity of antibody candidates, according to the companies.

If you like this content, please share it with a colleague!

Related Reading

ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

Serimmune, Merck reach drug discovery milestone
Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.

Twist's SARS-CoV-2 quality controls added to FDA materials
Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are...

Twist Bioscience partners with Miroculus on clinical products
Synthetic biology company Twist Bioscience announced on February 25 that it has initiated a collaboration with digital microfluidics developer Miroculus...

When will I begin receiving invitations to research studies?
Learn more about our user database and survey invitations in this FAQ.